Nano X Imaging Ltd (NNOX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Nano X Imaging Ltd.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 8 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 1.10 $ — 6% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight –
- Max. EBIT decline < 50% –
- Return on equity > 15% –
- ROCE > 15% –
- Expected return > 10% –
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 14.9% failed
- More than 10% revenue growth is expected for the coming year 90.4% passed
- Share count grows by less than 3% a year 7.4% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -330.2% failed
- Gross margin at 40% or higher and without meaningful erosion -98.2% failed
- Goodwill from acquisitions does not grow faster than revenue 0.2% passed
- Net debt below twice EBITDA 52 m net cash passed
- Operating cash flow covers the profits of the last three years 67 m failed
- Return on capital at 15% or higher, or up versus two years ago -41.8% failed
- Insiders hold at least 10% or are net buyers 0.4% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 427.3% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.12 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.22 | – | 3 | 25.20 | -468.70 | -11 | -12 |
| 2025: Q1 | -0.21 | – | 3 | 10.30 | -470.30 | -10 | -11 |
| 2025: Q2 | -0.23 | – | 3 | 12.60 | -484.30 | -9 | -10 |
| 2025: Q3 | -0.21 | – | 3 | 13.70 | -397.00 | -12 | -14 |
| 2025: Q4 | -0.50 | – | 4 | 24.00 | -897.40 | -12 | -13 |
| 2026: Q1 | -0.50 | – | 4 | 32.10 | -897.40 | -12 | -13 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Nano-X Imaging Ltd. entwickelt ein tomografisches Bildgebungsgerät in kommerzieller Qualität mit einer digitalen Röntgenquelle.
| Employees | 197 |
|---|---|
| Headquarters | Petah Tikva, Israel |
| Website | nanox.vision |
| IPO Date | 21. Aug 2020 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Erez I. Meltzer | CEO & Acting Chairman of the Board | 1957 |
| Ran Daniel | Chief Financial Officer | 1968 |
| Tamar Aharon Cohen | Executive VP & Chief Marketing Officer | 1977 |
| James M. Dara | GM of Source & Services Division and Head of Nanox USA | 1970 |
| Marina Gofman Feler | Chief Legal Officer | 1989 |
| Ilung Kim Ph.D. | Head of Nanox Korea | 1959 |
| Gali Yahav Attias | Chief of Corporate Resources | 1979 |
| Michael Yuz M.D., MBA | President & CMO, USARAD Holdings Inc. | – |
| Elli Yuz | CEO OF USARAD Holdings Inc. | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 29. Jul 2026 | Daniel Ran | CFO | Other | 1,000 | 0.89 | 890 |
| 28. Jul 2026 | Kainan Noga | Director | Buy | 33,000 | 0.90 | 29,700 |
| 27. Jul 2026 | Suesskind Dan S | Director | Buy | 25,000 | 0.92 | 23,000 |
| 27. Jul 2026 | Meltzer Erez | Chief Executive Officer | Buy | 36,000 | 0.93 | 33,480 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.